Chiuppesi, Flavia http://orcid.org/0000-0002-2921-5377
Zaia, John A.
Gutierrez-Franco, Miguel-Angel
Ortega-Francisco, Sandra http://orcid.org/0000-0002-4275-8253
Ly, Minh
Kha, Mindy
Kim, Taehyun
Dempsey, Shannon
Kar, Swagata
Grifoni, Alba
Sette, Alessandro http://orcid.org/0000-0001-7013-2250
Wussow, Felix http://orcid.org/0000-0001-7624-6734
Diamond, Don J. http://orcid.org/0000-0003-3579-7083
Funding for this research was provided by:
Carol Moss Foundation (N/A, N/A)
City of Hope Integrated Drug Development Venture program
Article History
Received: 2 November 2022
Accepted: 23 January 2024
First Online: 16 February 2024
Competing interests
: While unknown whether publication of this report will aid in receiving grants and contracts, it is possible that this publication will be of benefit to City of Hope (COH). COH had no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript. The authors declare the following competing interests: D.J.D. and F.W. are co-inventors on a patent application covering the design and construction of the synthetic MVA platform (PCT/US2021/016247). D.J.D., F.W., and F.C. are co-inventors on a patent application covering the development of a COVID-19 vaccine (PCT/US2021/032821) and provisional applications covering MPXV. D.J.D. is a consultant for GeoVax Labs and Helocyte Inc. A.F. is a consultant for Pfizer. A.S. is a consultant for Consultant for AstraZeneca Pharmaceuticals, Calyptus Pharmaceuticals, Inc, Darwin Health, EmerVax, EUROIMMUN, F. Hoffman-La Roche Ltd, Fortress Biotech, Gilead Sciences, Gritstone Oncology, Guggenheim Securities, Moderna, Pfizer, RiverVest Venture Partners, and Turnstone Biologics. All other authors declare no competing interests. GeoVax Labs Inc. has taken a worldwide exclusive license for COH04S1 under the name of GEO-CM04S1.